JPH10511557A - 血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法 - Google Patents
血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法Info
- Publication number
- JPH10511557A JPH10511557A JP9510447A JP51044797A JPH10511557A JP H10511557 A JPH10511557 A JP H10511557A JP 9510447 A JP9510447 A JP 9510447A JP 51044797 A JP51044797 A JP 51044797A JP H10511557 A JPH10511557 A JP H10511557A
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- binding
- polypeptide
- kdr
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.キナーゼドメイン結合領域(KDR)および/またはFMS−様チロシ ンキナーゼ結合領域(FLT−1)において突然変異を含んでいる脈管内皮細胞 増殖因子(VEGF)変異体をコードする配列を含む分離された核酸配列。 2.その変異体がアミノ酸約60から70までを含むFLT−1領域におけ る突然変異を含む請求項1のDNA配列。 3.その変異体がアミノ酸約78から95までを含むKDR領域における突 然変異を含む請求項1のDNA配列。 4.アミノ酸63、64、および67が修飾され、および/またはアミノ酸 82、84および86が修飾されている請求項1のDNA配列。 5.次の修飾: D63A、E64A、E67A、および/またはR82A、K84A、H86A を有する脈管内皮細胞増殖因子変異体をコードする請求項1のDNA配列。 6.各受容体に関する各領域の結合特性を修飾するようなキナーゼドメイン 領域(KDR)および/またはFMS様チロジンキナーゼ領域(FLT−1)に おける修飾を含む脈管内皮細胞増殖因子変異体を含むポリペプチド。 7.その変異体がアミノ酸60から70までを含む領域にアミノ酸の変化を 含む請求項6のポリペプチド。 8.その変異体がアミノ酸78から95までを含む領域にアミノ酸の変化を 含む請求項6のポリペプチド。 9.アミノ酸63、64および67が修飾されており、および/またはアミ ノ酸82、84および86が修飾されている請求項6のポリペプチド。 10.次の修飾: D63A、E64A、E67A、および/またはR82A、K84A、H86A を有する請求項6のポリペプチド。 11.さらにその他の点では本質的生物学的特性に影響のないアミノ酸修飾を 含む請求項6のポリペプチド。 12.形質転換された宿主細胞において請求項1のDNA配列を発現すること のできる複製可能な発現ベクター。 13.請求項12のベクターで形質転換された宿主細胞。 14.チャイニーズハムスター卵巣細胞である請求項13の宿主細胞。 15.請求項6のVEGF変異体を医薬的に許容される担体とともに含む組成 物。 16.請求項15の組成物を投与することを含む処置方法。 17.候補化合物を請求項6のポリペプチドと接触させて、その候補化合物が 有するそのポリペプチドのKDRおよび/またはFLT−1受容体への結合特性 に対する影響を測定することを含む、KDRおよび/またはFLT受容体の結合 に関して作動性または拮抗性を有する候補を確認するための検定法。 18.キナーゼドメイン受容体(KDR)領域にアミノ酸Ile46、Gln 79およびIle83および/またはIle43、Phe17およびGlu64 によって規定されるアミノ酸修飾を少なくとも1個含有する脈管内皮細胞増殖因 子(VEGF)変異体を含むポリペプチドであって、そのポリペプチドがKDR に対する結合親和性の機能的減少を示すもの。 19.各アミノ酸位置がおのおの修飾されている請求項18のポリペプチド。 20.そのアミノ酸位置の1個またはそれ以上が修飾されている請求項18の ポリペプチド。 21.その修飾がアラニンでの置換によるものである請求項18、19、また は20のいずれか1項のポリペプチド。 22.Ile46、Ile83、Glu64が修飾されている請求項18のポ リペプチド。 23.その修飾がアラニンでの置換によるものである請求項22のポリペプチ ド。 24.Phe17、Gln79、Ile43が修飾されている請求項18のポ リペプチド。 25.その修飾がアラニンでの置換によるものである請求項24のポリペプチ ド。 26.Ile46、Gln79、Ile83、Ile43が修飾されている請 求項18のポリペプチド。 27.その修飾がアラニンでの置換によるものである請求項26のポリペプチ ド。 28.Phe17、Glu64が修飾されている請求項18のポリペプチド。 29.Ile46、Gln79、Ile83、Ile43、Phe17、Gl u64が修飾されている請求項18のポリペプチド。 30.Phe17、Ile46、Ile83、Glu64が修飾されている請 求項18のポリペプチド。 31.Ile43、Ile46、Ile83、Glu64が修飾されている請 求項18のポリペプチド。 32.その修飾がアラニンでの置換によるものである請求項26、28、29 、30、または31のポリペプチド。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US282795P | 1995-08-25 | 1995-08-25 | |
US60/002,827 | 1995-08-25 | ||
US08/567,200 | 1995-12-05 | ||
US08/567,200 US6020473A (en) | 1995-08-25 | 1995-12-05 | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US08/691,791 | 1996-08-02 | ||
US08/691,791 US6592788B1 (en) | 1993-06-30 | 1996-08-02 | Method of manufacturing a dielectric lens for an antenna |
PCT/US1996/013621 WO1997008313A1 (en) | 1995-08-25 | 1996-08-23 | Variants of vascular endothelial cell growth factor, their uses, and processes for their production |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10511557A true JPH10511557A (ja) | 1998-11-10 |
JP3456706B2 JP3456706B2 (ja) | 2003-10-14 |
Family
ID=26670933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51044797A Expired - Lifetime JP3456706B2 (ja) | 1995-08-25 | 1996-08-23 | 血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法 |
Country Status (10)
Country | Link |
---|---|
US (4) | US6020473A (ja) |
EP (1) | EP0851920B1 (ja) |
JP (1) | JP3456706B2 (ja) |
AT (1) | ATE399203T1 (ja) |
AU (1) | AU6857296A (ja) |
CA (1) | CA2230144C (ja) |
DE (1) | DE69637570D1 (ja) |
DK (1) | DK0851920T3 (ja) |
ES (1) | ES2309990T3 (ja) |
WO (1) | WO1997008313A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541849A (ja) * | 1999-04-16 | 2002-12-10 | ジェネンテック・インコーポレーテッド | 血管内皮細胞増殖因子変異体とその用途 |
JP2009511492A (ja) * | 2005-10-06 | 2009-03-19 | トロフォゲン,インコーポレイテッド | Vegf類縁体および使用方法 |
JP2010506171A (ja) * | 2006-10-04 | 2010-02-25 | ジェネンテック インコーポレイテッド | Vegfのためのelisa |
US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
US10544200B2 (en) | 2013-11-05 | 2020-01-28 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
US10766941B2 (en) | 2012-07-30 | 2020-09-08 | Trophogen Inc. | Glycoprotein hormone long-acting superagonists |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US7005505B1 (en) * | 1995-08-25 | 2006-02-28 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
US6416967B2 (en) * | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
US5728541A (en) * | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US20040023375A1 (en) * | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
US20040072722A1 (en) | 2002-10-10 | 2004-04-15 | Kornblith Paul L. | Methods for assessing efficacy of chemotherapeutic agents |
US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
US6485942B1 (en) * | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
US6635421B1 (en) | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
WO1999030157A2 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Neuropilins in methods for diagnosis and prognosis of cancer |
EP1053326A2 (en) | 1998-02-06 | 2000-11-22 | Collateral Therapeutics | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf |
AU2004202596B2 (en) * | 1999-04-16 | 2007-06-14 | Genentech, Inc. | Vascular endothelial cell growth factor variants and uses thereof |
US7090834B1 (en) * | 1999-04-16 | 2006-08-15 | Genentech, Inc. | Vascular endothelial cell growth factor variants and uses thereof |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
NZ514918A (en) | 1999-04-28 | 2003-11-28 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
CA2373822A1 (en) | 1999-05-20 | 2000-11-30 | Scios Inc. | Vascular endothelial growth factor variants |
WO2001025277A1 (en) * | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
US7078382B1 (en) * | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
EP1225910A2 (en) * | 1999-11-02 | 2002-07-31 | Genentech, Inc. | MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
AU2000230635A1 (en) * | 2000-01-20 | 2001-07-31 | North Bristol Nhs Trust | Vegf148 isoform, a truncated splice variant of vegf. vegf heterodimers and therapeutical uses thereof |
US7355019B2 (en) * | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
EP1303594A4 (en) * | 2000-07-26 | 2004-07-14 | Ludwig Inst Cancer Res | GLYCOSYLATED VEGF-B AND METHOD FOR INCREASING THE QUANTITY OF SOLUBLE VEGF-B |
KR100419972B1 (ko) * | 2000-09-09 | 2004-03-03 | 굿젠 주식회사 | 링커 염기서열로 연결된 인간 vegf의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질 |
US20020151489A1 (en) * | 2000-10-02 | 2002-10-17 | St. Elizabeth's Medical Center Of Boston, Inc. | Use of lymphangiogenic agents to treat lymphatic disorders |
AU2002338313A1 (en) * | 2001-04-06 | 2002-10-21 | Maxygen Holdings Ltd. | Single chain dimeric polypeptides derived from the vegf family |
JPWO2002100441A1 (ja) * | 2001-06-08 | 2004-09-24 | 株式会社ディナベック研究所 | 血管再生療法 |
WO2004058821A2 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US20060269548A1 (en) * | 2001-07-12 | 2006-11-30 | Kari Alitalo | Lymphatic endothelial cells materials and methods |
WO2003022874A1 (en) * | 2001-09-12 | 2003-03-20 | Beijing Institute For Cancer Research | Antagonist peptides to vegr receptor flt-1 |
US20040086888A1 (en) * | 2001-10-18 | 2004-05-06 | Kornblith Paul L | Method for tandem genomic/proteomic analysis of proliferating cells |
US7985402B2 (en) * | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7211240B2 (en) * | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US20050100963A1 (en) * | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
EP1342783A1 (de) * | 2002-03-08 | 2003-09-10 | Eming, Sabine, A.,Dr. med. | Proteolyseresistenter aktiver VEGF |
CA2486270C (en) * | 2002-06-05 | 2015-07-28 | Genentech, Inc. | Vegfr modulating agents and methods for liver growth and liver protection |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
NZ541480A (en) | 2003-03-12 | 2008-03-28 | Genentech Inc | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
JP2005110508A (ja) * | 2003-10-02 | 2005-04-28 | Nec Soft Ltd | 血管内皮増殖因子受容体2型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途 |
CN1304427C (zh) * | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
EP1767546B1 (en) * | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
WO2005121316A1 (en) * | 2004-06-11 | 2005-12-22 | Bernard O'brien Institute Of Microsurgery | Tissue material and muscle derived matrix |
WO2006014899A2 (en) | 2004-07-26 | 2006-02-09 | Dow Global Technologies Inc. | Process for improved protein expression by strain engineering |
US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
JP2008513356A (ja) * | 2004-08-09 | 2008-05-01 | アリオス バイオファーマ インク. | 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法 |
EP1929306A4 (en) * | 2005-09-01 | 2009-11-11 | Precision Therapeutics Inc | CHEMOSENSIBLE ASSAYS, THE TUMOR CELLS WITH PERSISTENT PHENOTYPICAL CHARACTERISTICS |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
EA200801170A1 (ru) * | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
CN101454018A (zh) * | 2006-03-27 | 2009-06-10 | 健泰科生物技术公司 | 用于治疗肾病症的方法 |
AU2013221919B2 (en) * | 2006-10-04 | 2016-04-14 | Genentech, Inc. | ELISA for VEGF |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
AU2008245696B2 (en) | 2007-04-27 | 2013-11-07 | Pelican Technology Holdings, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CN101679511A (zh) * | 2007-06-06 | 2010-03-24 | 杜门蒂斯有限公司 | 多肽、抗体可变域和拮抗剂 |
WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
US8741839B2 (en) | 2009-01-18 | 2014-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin |
NZ605449A (en) | 2010-07-09 | 2015-03-27 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
US20180369334A1 (en) * | 2015-01-16 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Vegf variant polypeptide compositions |
EP3216458A1 (en) | 2016-03-07 | 2017-09-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified vascular endothelial growth factor a (vegf-a) and its medical use |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3887699A (en) * | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) * | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) * | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4195128A (en) * | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) * | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) * | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) * | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
PH19942A (en) * | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
NZ201918A (en) * | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
HUT35524A (en) * | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3413608A1 (de) * | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
IL74909A (en) * | 1984-04-20 | 1992-01-15 | Genentech Inc | Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein |
JPS63502716A (ja) * | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
EP0266032A1 (en) * | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
US5332671A (en) * | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
DE69229454T2 (de) * | 1991-03-28 | 2000-01-05 | Merck & Co Inc | Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors |
DE9104598U1 (ja) | 1991-04-16 | 1992-10-01 | Natec Reich, Summer Gmbh & Co Kg, 8996 Opfenbach, De | |
US5607918A (en) * | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
CA2370246C (en) * | 1999-04-16 | 2017-03-21 | Genentech, Inc. | Vascular endothelial cell growth factor variants and uses thereof |
US7090834B1 (en) * | 1999-04-16 | 2006-08-15 | Genentech, Inc. | Vascular endothelial cell growth factor variants and uses thereof |
-
1995
- 1995-12-05 US US08/567,200 patent/US6020473A/en not_active Expired - Lifetime
-
1996
- 1996-08-02 US US08/691,794 patent/US6057428A/en not_active Expired - Lifetime
- 1996-08-23 AT AT96929012T patent/ATE399203T1/de not_active IP Right Cessation
- 1996-08-23 WO PCT/US1996/013621 patent/WO1997008313A1/en active Application Filing
- 1996-08-23 DK DK96929012T patent/DK0851920T3/da active
- 1996-08-23 ES ES96929012T patent/ES2309990T3/es not_active Expired - Lifetime
- 1996-08-23 DE DE69637570T patent/DE69637570D1/de not_active Expired - Lifetime
- 1996-08-23 EP EP96929012A patent/EP0851920B1/en not_active Expired - Lifetime
- 1996-08-23 CA CA2230144A patent/CA2230144C/en not_active Expired - Lifetime
- 1996-08-23 JP JP51044797A patent/JP3456706B2/ja not_active Expired - Lifetime
- 1996-08-23 AU AU68572/96A patent/AU6857296A/en not_active Abandoned
-
2005
- 2005-06-03 US US11/145,494 patent/US7427596B2/en not_active Expired - Fee Related
-
2006
- 2006-09-28 US US11/536,471 patent/US20070082847A1/en not_active Abandoned
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541849A (ja) * | 1999-04-16 | 2002-12-10 | ジェネンテック・インコーポレーテッド | 血管内皮細胞増殖因子変異体とその用途 |
JP2009511492A (ja) * | 2005-10-06 | 2009-03-19 | トロフォゲン,インコーポレイテッド | Vegf類縁体および使用方法 |
JP2013177458A (ja) * | 2005-10-06 | 2013-09-09 | Trophogen Inc | Vegf類縁体および使用方法 |
US9078860B2 (en) | 2005-10-06 | 2015-07-14 | Trophogen, Inc. | VEGF analogs |
JP2010506171A (ja) * | 2006-10-04 | 2010-02-25 | ジェネンテック インコーポレイテッド | Vegfのためのelisa |
US9146245B2 (en) | 2006-10-04 | 2015-09-29 | Genentech, Inc. | ELISA for VEGF |
US9625462B2 (en) | 2006-10-04 | 2017-04-18 | Genetech, Inc. | Elisa for VEGF |
US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
US10766941B2 (en) | 2012-07-30 | 2020-09-08 | Trophogen Inc. | Glycoprotein hormone long-acting superagonists |
US10544200B2 (en) | 2013-11-05 | 2020-01-28 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
Also Published As
Publication number | Publication date |
---|---|
JP3456706B2 (ja) | 2003-10-14 |
EP0851920B1 (en) | 2008-06-25 |
ATE399203T1 (de) | 2008-07-15 |
AU6857296A (en) | 1997-03-19 |
US6020473A (en) | 2000-02-01 |
DE69637570D1 (de) | 2008-08-07 |
ES2309990T3 (es) | 2008-12-16 |
DK0851920T3 (da) | 2008-09-22 |
US20060024785A1 (en) | 2006-02-02 |
WO1997008313A1 (en) | 1997-03-06 |
CA2230144A1 (en) | 1997-03-06 |
US20070082847A1 (en) | 2007-04-12 |
US7427596B2 (en) | 2008-09-23 |
US6057428A (en) | 2000-05-02 |
EP0851920A1 (en) | 1998-07-08 |
CA2230144C (en) | 2013-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10511557A (ja) | 血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法 | |
JP3117992B2 (ja) | 血管内皮細胞成長因子の生産およびそれをコードするdna | |
US6750044B1 (en) | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids | |
US6384191B1 (en) | Receptors for fibroblast growth factors | |
US5352587A (en) | Compositions and methods for the synthesis of natriuretic protein receptor B and methods of use | |
JPH07508420A (ja) | 肝細胞成長因子変異体 | |
HU219674B (hu) | Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra | |
JP2003530867A (ja) | トロンボポエチン受容体モジュレートペプチド | |
JP2002541849A (ja) | 血管内皮細胞増殖因子変異体とその用途 | |
US7005505B1 (en) | Variants of vascular endothelial cell growth factor | |
JP2004194665A (ja) | 血管内皮細胞増殖因子の変異体 | |
WO1998036075A9 (en) | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and related aspects thereof | |
US20030108989A1 (en) | Production of vascular endothelial cell growth factor and DNA encoding same | |
JPH1156378A (ja) | 変異型ヒト成長ホルモンとその用途 | |
US20030092617A1 (en) | Production of vascular endothelial cell growth factor and DNA enconding same | |
JPH1080277A (ja) | 変異型ヒト成長ホルモンとその用途 | |
AU2004202596A1 (en) | Vascular endothelial cell growth factor variants and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080801 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080801 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090801 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090801 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100801 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110801 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110801 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120801 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130801 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |